Eversense Buzz Continues with New Collaboration

Senseonics said it will integrate its Eversense CGM with Glooko’s diabetes management platform.

Two powerhouses in the diabetes treatment and management space are in a new collaboration. Senseonics, which has been buzzing since receiving a PMA for the Eversense continuous glucose monitoring CGM system in June, and Glooko have announced a new agreement.

The partnership enables integration of the long-term Eversense branded CGM systems with Glooko’s diabetes data management platform.

The integration of these solutions will allow Eversense CGM data to be synced into Mountain View, CA-based Glooko’s platform directly from the Germantown, MD -based Senseonics cloud. The companies said that Eversense users will be able to view historical glucose and related data both in Glooko’s Mobile and Web Apps and will continue to get real-time readings from their Eversense Mobile Application. Healthcare professionals may view their patients’ data in the Glooko Population Tracker in interactive reports alongside other data resident in Glooko.

The implementation of the Glooko’s solution with Eversense could occur by the end of the year. The companies said the agreement covers all markets where the Eversense and Glooko technology is available.

“With this integration, users can consolidate their glucose data with insulin, meals, medication and exercise to help them see glycemic patterns more readily. Glooko allows our users to take full advantage of both companies’ platforms and the large amount of data from our Eversense and Eversense XL systems,” Tim Goodnow, president and CEO of Senseonics, said in a release. “Partnering with an innovative platform like Glooko fits with our strategy of giving people the tools to use all of their health data to conveniently and confidently make actionable lifestyle decisions.”

The collaboration with Glooko comes on the heels of Senseonics partnering with Beta Bionics. Under the agreement, Beta Bionics would integrate the Eversense CGM system with the iLet, a bionic pancreas system. The Boston, MA-based company recently received an IDE for the iLet.


500 characters remaining